Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets

Coombs, G.H., Goldberg, D.E., Klemba, M., Berry, C. , Kay, J. and Mottram, J.C. (2001) Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends in Parasitology, 17(11), pp. 532-537. (doi: 10.1016/S1471-4922(01)02037-2)

Full text not currently available from Enlighten.

Abstract

All parasitic protozoa contain multiple proteases, some of which are attracting attention as drug targets. Aspartic proteases are already the targets of some clinically useful drugs (e.g. chemotherapy of HIV infection) and a variety of factors make these enzymes appealing to those seeking novel antiparasite therapies. This review provides a critical analysis of the current knowledge on Plasmodium aspartic proteases termed plasmepsins, proposes a definitive nomenclature for this group of enzymes, and compares these enzymes with aspartic proteases of humans and other parasitic protozoa. The present status of attempts to obtain specific inhibitors of the parasite enzymes that will be useful as drugs is outlined and suggestions for future research priorities are proposed.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Berry, Professor Colin and Mottram, Professor Jeremy and Coombs, Professor Graham
Authors: Coombs, G.H., Goldberg, D.E., Klemba, M., Berry, C., Kay, J., and Mottram, J.C.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Trends in Parasitology
ISSN:1471-4922
Published Online:21 February 2002

University Staff: Request a correction | Enlighten Editors: Update this record